Search for: "Ortho-McNeil Pharmaceutical, LLC" Results 21 - 40 of 41
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 May 2010, 4:57 pm by mcarzima@imediainc.com
Two subsidiaries of Johnson & Johnson, Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., have agreed to pay more than $81 million to settle allegations that they violated the False Claims Act by illegally promoting the epilepsy drug, Topomax. [read post]
11 May 2010, 7:07 pm by Carey, Danis & Lowe, L.L.C.
The suit names Johnson & Johnson, Ortho-McNeil Pharmaceuticals Inc. and Johnson & Johnson Pharmaceutical Research and Development LLC as defendants to Presley's claim. [read post]
3 May 2010, 11:01 am by Ben Vernia
The District Court in Boston has posted the plea agreement and criminal Information filed against Ortho-McNeil Pharmaceutical, LLC, in the settlement announced last week by the Department of Justice. [read post]
2 May 2010, 6:32 pm by Shawn Cantley
Ortho-McNeil Pharmaceutical LLC, agreed to pay a $6.14 mil criminal fine and plead guilty to a misdemeanor for misbranding Topamax in violation of the Food, Drug and Cosmetic Act. [read post]
29 Apr 2010, 1:26 pm
The settlement arose from two whistleblower cases filed under federal and state False Claims Acts, alleging that Otho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals, Inc., improperly marketed Topamax for psychiatric uses, when it was only FDA-approved to treat epilepsy. [read post]
29 Apr 2010, 1:26 pm
The settlement arose from two whistleblower cases filed under federal and state False Claims Acts, alleging that Otho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals, Inc., improperly marketed Topamax for psychiatric uses, when it was only FDA-approved to treat epilepsy. [read post]
29 Apr 2010, 2:06 am by Ben Vernia
The Department of Justice announced on April 29 that Ortho-McNeil Pharmaceutical, LLC, and Ortho-McNeil-Janssen Pharmaceuticals, Inc., two subsidiaries of Johnson & Johnson, have agreed to pay $81 million to settle charges brought in two whistleblower suits that they violated the False Claims Act by promoting Topamax for off-label (unapproved) uses. [read post]
23 Apr 2010, 8:20 am by Press Releases
., Bose, Brigham Young University, Cornell University, Stanford University, Duke University, Georgetown University, GlaxoSmithKline, Honeywell, Harvard University, Johnson & Johnson, Kauffman Foundation, Lockheed Martin, Massachusetts Institute of Technology (MIT), Mayo Clinic, Ortho-McNeil Pharmaceuticals Inc., Rutgers, Syngenta Biotechnology, Scripps Research Institute, U.S. [read post]
31 Mar 2010, 1:58 pm
Pressure Products Medical Supplies invented a valve remover for an introducer, netting 5,125,904 & 5,312,355. [read post]
17 Feb 2010, 8:00 am by Karen E. Keller
(patent infringement) 1/8: Alza Corporation and Ortho-McNeil-Janssen Pharmaceuticals Inc. v. [read post]
22 Sep 2009, 5:32 am
William Dowling filed a lawsuit Thursday against J&J and its units Ortho McNeil Pharmaceutical Inc. and Johnson & Johnson Pharmaceutical Research and Development LLC. [read post]
28 Aug 2009, 8:11 am
(patent infringement) 9/4: Purdue Pharma Products LP, Napp Pharmaceutical Group Ltd., Ortho-McNeil-Janssen Pharmaceuticals Inc. v. [read post]
29 Aug 2008, 1:25 pm
: (IP finance), Facebook removes international access to Scrabulous, except from India: (Ars Technica), (Techdirt), Reverse engineering can resolve conflict between standardisation and competition: (Techdirt), Benefits of piracy aren’t always in the expected places: (Techdirt)   Events 1-3 September: Federation of Indian Chambers of Commerce and Industry, Department of Industrial Property and Promotion, and WIPO conference on ‘Development and IP: Building synergies… [read post]
11 Jul 2008, 4:30 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
2 May 2008, 7:00 am
: (Spicy IP), Ultracet (Tramadol) – Barr and Caraco win summary judgment that Ortho-McNeil’s formulation patent on Ultracet is invalid: (Orange Book Blog), Xopenex (Levosalbutamol) – US: Sepracor, Breath settle Xopenex patent fight: (IP Law360), (GenericsWeb), Africa African copyright & access to knowledge (ACA2K) project launched: (Michael Geist), (Afro-IP), Seven reasons why Prof Odek should be the next WIPO DG: (Afro-IP), … [read post]
18 Apr 2008, 2:00 am
Lélos Kai Sia EE (and Others) v GlaxoSmithKline AEVE: (IPKat), US: Bio commends Sen Specter for patent reform stance: (Patent Docs), US: USPTO rules on two of four neural stem cell patents in dispute between StemCells Inc and Neuralstem Inc; parties disagree on how extensively claims amended: (IP Law360), (IPBiz), US: Insmed continues fight for generic biologic approval: (GenericsWeb), Pharma & Biotech - Products Cipralex (Escitalopram) – Lundbeck wins… [read post]
11 Apr 2008, 9:00 am
No problem…: Lundbeck A/S v Generics UK Ltd & Ors: (IPKat), Exelon (Rivastigmine Tartrate) – Dr Reddy’s and Novartis settle Exelon patent dispute: (Therapeutics Daily), GeneMaker – Codon Devices, Blue Heron Biotechnology settle patent suit over gene synthesis platform: (Patent Docs), Glucophage (Metformin) – Depomed settles patent litigation against IVAX: (SmartBrief), (IP Law360), (GenericsWeb), Lexapro (Escitalopram)… [read post]
4 Apr 2008, 1:00 am
: (IPBiz) Pharma & Biotech - Products Abilify (Aripiprazole) – Otsuka files US patent infringement suit against Teva over seeking approval for generic Abilify: (IP Law360), Aricept (Donepezil) – US federal judge grants Eisai’s request for preliminary injunction blocking Teva from marketing generic version of Aricept: (IP Law360), (Orange Book Blog), Carbatrol (Carbamazepine) – US federal judge delivers mixed ruling in Shire… [read post]
25 Jan 2008, 1:00 am
: (Generic Pharmaceuticals & IP),Arava (Leflunomide) - Sanofi-Aventis loses bid to dismiss Louisiana Wholsesale Drug Co's antitrust claims accusing S-A of unlawfully blocking generic competition for Arava by filing a sham Citizen Petition with the USFDA: (IP Law360),Ciprofloxacin - CIPLA issued notice by National Pharmaceutical Pricing Authority for allegedly overpricing its antibiotic Ciprofloxacin (especially of note because CIPLA … [read post]